NASDAQ:SPRC SciSparc (SPRC) Stock Price, News & Analysis $4.63 +0.40 (+9.46%) Closing price 03:58 PM EasternExtended Trading$4.58 -0.05 (-1.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About SciSparc Stock (NASDAQ:SPRC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SciSparc alerts:Sign Up Key Stats Today's Range$4.27▼$5.0750-Day Range$4.17▼$8.1952-Week Range$4.00▼$37.59Volume431,454 shsAverage Volume40,536 shsMarket Capitalization$2.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Read More Receive SPRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SciSparc and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRC Stock News HeadlinesSciSparc Announces Patent Filing and Merger UpdatesAugust 8, 2025 | theglobeandmail.comSciSparc and Clearmind Publish Patent for Novel Obesity TherapyAugust 8, 2025 | tipranks.comCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 22 at 2:00 AM | Investors Alley (Ad)SciSparc Ltd. and Clearmind Medicine Inc. Collaborate to Launch International Patent Application for Innovative Therapy Targeting Metabolic Syndrome and ObesityAugust 7, 2025 | quiverquant.comQSciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood SugarAugust 7, 2025 | globenewswire.comSciSparc Ltd: SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECJuly 31, 2025 | finanznachrichten.deSciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECJuly 30, 2025 | globenewswire.comClearmind Medicine files international patent application under PCTJuly 30, 2025 | msn.comSee More Headlines SPRC Stock Analysis - Frequently Asked Questions How have SPRC shares performed this year? SciSparc's stock was trading at $7.56 at the beginning of the year. Since then, SPRC shares have decreased by 38.8% and is now trading at $4.63. When did SciSparc's stock split? SciSparc shares reverse split before market open on Thursday, July 3rd 2025.The 1-21 reverse split was announced on Tuesday, June 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of SciSparc? Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SciSparc own? Based on aggregate information from My MarketBeat watchlists, some other companies that SciSparc investors own include Solid Power (SLDP), Sangamo Therapeutics (SGMO), Plug Power (PLUG), NVIDIA (NVDA), Verb Technology (VERB) and Avalon GloboCare (ALBT). Company Calendar Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRC CIK1611746 Webscisparc.com Phone972-3717-5777FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.36 Quick Ratio5.28 Sales & Book Value Annual Sales$1.31 million Price / Sales1.91 Cash FlowN/A Price / Cash FlowN/A Book Value$18.13 per share Price / Book0.26Miscellaneous Outstanding Shares530,000Free Float527,000Market Cap$2.50 million OptionableNot Optionable Beta0.88 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:SPRC) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.